TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25450120

Group type: EXPERIMENTAL
Intervention: Horizontal adduction stretching with manual scapular stabilization (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Horizontal adduction stretching without stabilization (n=30)
Number of subjects: 60
Study: 23265334

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 1376

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Higher proportion of time spent in sinus rhythm
Number of subjects: 1376
Study: 21210833

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo treatment (control group)
Number of subjects: 42
Study: 19329457

Group type: COMPARATOR
Intervention: 0% hydrogen peroxide
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 3.6% hydrogen peroxide
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 30% hydrogen peroxide
Number of subjects: 65
Study: 16827024

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (350mJ/2Hz) with Fuji II LC (GC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (350mJ/2Hz) with Vitremer (3M)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbide bur (control group) with Fuji II LC (GC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbide bur (control group) with Vitremer (3M)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (350mJ/2Hz) with Fuji II LC (GC) on dentin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (350mJ/2Hz) with Vitremer (3M) on dentin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbide bur (control group) with Fuji II LC (GC) on dentin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbide bur (control group) with Vitremer (3M) on dentin
Number of subjects: 20
Study: 16167748

Group type: EXPERIMENTAL
Intervention: Early feeding group (sips of water within 6-8 hours, followed by oral soup or milk at least 150 millilitres at a time within 8-12 hours post-operative)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Early feeding group
Number of subjects: 192

Group type: COMPARATOR
Intervention: Routine feeding group (restricted oral intake for 24 hours, administration of oral sips of water 24-48 hours post-operative)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Routine feeding group
Number of subjects: 192
Study: 11153864

Group type: EXPERIMENTAL
Intervention: Landmark group (learning a route on a map that included landmarks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: No-landmark group (learning a route on a map without landmarks)
Number of subjects: 67
Study: 8956916

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg/day
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 1347222

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.5 mg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nondepolarizing regimen with doses ranging from approximately 1.5 to 6 times the ED95, with or without a priming dose
Number of subjects: 75
Study: 2939008

Group type: EXPERIMENTAL
Intervention: Combination of probucol and colestipol (treatment group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 28
Study: 30340627

Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification (ABM) training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard attentional bias task (non-treatment)
Number of subjects: 90
Study: 26293156

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided popliteal sciatic nerve block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 60
Study: 24794880

Group type: EXPERIMENTAL
Intervention: Modified Cognitive Adaptation Training (CAT)
Number of subjects: 23
Study: 22568773

Group type: EXPERIMENTAL
Intervention: Respiratory-gated auricular vagal afferent nerve stimulation (RAVANS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonvagal auricular stimulation (NVAS)
Number of subjects: 15
Study: 20116631

Group type: EXPERIMENTAL
Intervention: Virosome vaccine (n=43)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Split vaccine (n=47)
Number of subjects: 90
Study: 18590393

Group type: EXPERIMENTAL
Intervention: Preoperative nerve block (NB) with 0.25% 5‐8 ml bupivacaine mixed with 20‐40 mg methylprednisolone
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Preoperative nerve block (NB)
Number of subjects: 39
Study: 15960999

Group type: EXPERIMENTAL
Intervention: Emergency physicians wore white coats and formal attire
Number of subjects: 111

Group type: COMPARATOR
Intervention: Emergency physicians wore scrubs
Number of subjects: 111
Study: 12468165

Group type: EXPERIMENTAL
Intervention: Hormone therapy (conjugated estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg)
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study: 10627846

Group type: EXPERIMENTAL
Intervention: In-flight pulsations during saccades
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7671159

Group type: EXPERIMENTAL
Intervention: Calcitonin 40 IU/day i.m. (n = 17)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sodium ethiodronate 400 mg p.o., 15 days every 3 months (n = 23)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched Spanish controls)
Number of subjects: 120
Study: 2248063

Group type: EXPERIMENTAL
Intervention: Moclobemide (reversible inhibitor of monoamine oxidase-A)
Number of subjects: 763

Group type: COMPARATOR
Intervention: Tricyclics
Number of subjects: 763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 763
Study: 7312606

Group type: EXPERIMENTAL
Intervention: Fiberoptic gastroscopy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Barium meal
Number of subjects: 103
Study: 31917283

Group type: EXPERIMENTAL
Intervention: Mucidosphaerium sp. (MS)
Number of subjects: 0
Study: 29718385

Group type: EXPERIMENTAL
Intervention: BI 409306 (10 mg)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: BI 409306 (25 mg)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: BI 409306 (50 mg)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: BI 409306 (100 mg)
Number of subjects: 518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study: 28809935

Group type: EXPERIMENTAL
Intervention: PM+ (Problem Management Plus)
Number of subjects: 421

Group type: COMPARATOR
Intervention: EUC (Enhanced Usual Care)
Number of subjects: 421
Study: 24219753

Group type: EXPERIMENTAL
Intervention: Early urinary catheter clamping protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study: 23246078

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Lung cancer
Number of subjects: 234
Study: 21488933

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment
Number of subjects: 93

Group type: COMPARATOR
Intervention: Continued smoking or oscillated
Number of subjects: 93
Study: 17659838

Group type: EXPERIMENTAL
Intervention: High frequency TENS (n=81)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Sham TENS (n=82)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: High frequency TENS
Number of subjects: 163
Study: 16720619

Group type: EXPERIMENTAL
Intervention: Dr Atkins' new diet revolution
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Slim‐Fast plan
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Weight Watchers pure points programme
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rosemary Conley's eat yourself slim diet and fitness plan
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 15241356

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixture of 4 bacterial species (MIX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10940952

Group type: EXPERIMENTAL
Intervention: CPR training
Number of subjects: 196

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 196
Study: 9075631

Group type: EXPERIMENTAL
Intervention: Psoas training (60 hip flexions in sitting position with a 5 kg weight on the knee) for 3 years
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no psoas training) for 3 years
Number of subjects: 67

Group type: COMPARATOR
Intervention: Crossover from control to training after 1 year
Number of subjects: 67
Study: 8471409

Group type: EXPERIMENTAL
Intervention: 100 mg vanoxerine after fasting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg vanoxerine after low-fat meal
Number of subjects: 12
Study: 3803702

Group type: EXPERIMENTAL
Intervention: Esaprazole 600 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Esaprazole 900 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29571915

Group type: EXPERIMENTAL
Intervention: Resin-based sealer (AH Plus)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bioceramic sealer (Total Fill)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 61
Study: 27821601

Group type: EXPERIMENTAL
Intervention: Smokerface poster campaign
Number of subjects: 9851

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9851
Study: 25015535

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 112

Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 112
Study: 22577648

Group type: EXPERIMENTAL
Intervention: Socket preservation (SP) with bovine bone mineral and porcine collagen membrane
Number of subjects: 41

Group type: COMPARATOR
Intervention: Extraction alone (EXT)
Number of subjects: 41
Study: 20819587

Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (r-Sak or rt-PA)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Rescue PCI
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with rescue PCI
Number of subjects: 311
Study: 18308888

Group type: EXPERIMENTAL
Intervention: Walking programme (WP)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Vitamin B supplementation (FA/B12/B6)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Low-intensity placebo activity programme
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 152
Study: 15644824

Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 12618057

Group type: EXPERIMENTAL
Intervention: Selegiline alone (n = 10)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Levopoda/Carbidopa alone (n = 49)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Selegiline and Levodopa/Carbidopa combined (n = 36)
Number of subjects: 95
Study: 10391253

Group type: COMPARATOR
Intervention: Cold perfusion temperature (20 degrees C)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Tepid perfusion temperature (32 degrees C)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Warm perfusion temperature (37 degrees C)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 291
Study: 8894721

Group type: EXPERIMENTAL
Intervention: Trapezius microcurrent therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Earlobe microcurrent stimulation (CES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 30
Study: 1815069

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 100 mg sulpiride
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 100 mg sulpiride
Number of subjects: 27
Study: 6404341

Group type: EXPERIMENTAL
Intervention: High dose prednisolone (33 patients)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Low dose prednisolone (34 patients)
Number of subjects: 67
Study: 31001673

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg/day
Number of subjects: 296

Group type: COMPARATOR
Intervention: Glimepiride (control)
Number of subjects: 296
Study: 30505604

Group type: EXPERIMENTAL
Intervention: Metoprolol (0.1 mg kg‐1) and tramadol (1 mg kg‐1)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Remifentanil (0.5 μg kg‐1 bolus followed by 0.25‐0.5 μg kg‐1 min‐1 infusion)
Number of subjects: 88
Study: 26990931

Group type: EXPERIMENTAL
Intervention: R-COMP (rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone)
Number of subjects: 414

Group type: COMPARATOR
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: R-COMP
Number of subjects: 414

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 414
Study: 23834392

Group type: EXPERIMENTAL
Intervention: Combined inhalation of beta2-agonists (salbutamol, formoterol, salmeterol)
Number of subjects: 30
Study: 22230919

Group type: EXPERIMENTAL
Intervention: Expectorated saliva osmolality measured during dehydration trials
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single-threshold cutoffs for saliva osmolality
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Double-threshold detection technique for saliva osmolality
Number of subjects: 12
Study: 19464026

Group type: EXPERIMENTAL
Intervention: Pramlintide 15 microg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pramlintide 30 microg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pramlintide (both doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 12
Study: 17535711

Group type: EXPERIMENTAL
Intervention: Irradiated allograft saphenous vein (group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fresh allograft (group B)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fresh self-graft (group C)
Number of subjects: 34
Study: 16075574

Group type: EXPERIMENTAL
Intervention: Child health and nutrition interventions, specific details not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study: 11801508

Group type: EXPERIMENTAL
Intervention: Latanoprost once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Unoprostone twice daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Latanoprost added to unoprostone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Unoprostone added to latanoprost
Number of subjects: 32
Study: 9695964

Group type: EXPERIMENTAL
Intervention: Interferon alpha, 3 x 10(6) units/m2 subcutaneously three times weekly until relapse
Number of subjects: 85

Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Interferon alpha
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 7986464

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily (n = 77)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Nicardipine 50 mg twice daily (n = 77)
Number of subjects: 154
Study: 2723246

Group type: EXPERIMENTAL
Intervention: Fentanyl intravenously (3 micrograms/kg) prior to surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30397904

Group type: EXPERIMENTAL
Intervention: Acupuncture at P6 plus antiemetics (n = 86)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Anti-emetics only (n = 75)
Number of subjects: 161
Study: 28237958

Group type: EXPERIMENTAL
Intervention: e‐intervention Tabac Info Service (e‐TIS)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Current practices (Control)
Number of subjects: 3000
Study: 25817374

Group type: EXPERIMENTAL
Intervention: Immediate delivery
Number of subjects: 703

Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 703
Study: 22836633

Group type: COMPARATOR
Intervention: Normal laboratory condition (N)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cold field condition (C)
Number of subjects: 12
Study: 21146770

Group type: EXPERIMENTAL
Intervention: Starting The Conversation (STC) dietary assessment tool
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 463
Study: 19917166

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: High homocysteine levels
Number of subjects: 235
Study: 16396765

Group type: EXPERIMENTAL
Intervention: High-dose mitoxantrone combined with once daily cytarabine
Number of subjects: 165
Study: 14700448

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) strategies, including maximally tolerated doses, switching medications, combining dissimilar medications, and combining psychotherapy with medication.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy (current first-line standard of care)
Number of subjects: 0
Study: 12374491

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 300 mg/d
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 600 mg/d
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 1200 mg/d
Number of subjects: 80
Study: 9879213

Group type: EXPERIMENTAL
Intervention: Scanora
Number of subjects: 254

Group type: COMPARATOR
Intervention: Conventional (panoramic + intra-oral radiographs)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 254
Study: 8026236

Group type: EXPERIMENTAL
Intervention: 90-ml oral sodium phosphate preparation
Number of subjects: 450

Group type: COMPARATOR
Intervention: 4-liter polyethylene glycol solution
Number of subjects: 450

Group type: COMPARATOR
Intervention: sulfate-free 4-liter polyethylene glycol solution
Number of subjects: 450
Study: 2607910

Group type: COMPARATOR
Intervention: Fentanyl 3 ug/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fentanyl 3 ug/kg plus aminophylline 3 mg/kg iv
Number of subjects: 12
Study: 31876900

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly or every 2 weeks
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 4 weeks
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 8 weeks
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 31288352

Group type: EXPERIMENTAL
Intervention: 2.2-mm clear corneal incision
Number of subjects: 131

Group type: COMPARATOR
Intervention: 3.0-mm clear corneal incision
Number of subjects: 131
Study: 28343413

Group type: EXPERIMENTAL
Intervention: Corner store intervention
Number of subjects: 9347

Group type: EXPERIMENTAL
Intervention: Wholesaler intervention
Number of subjects: 9347
Study: 26061267

Group type: EXPERIMENTAL
Intervention: Ketamine and midazolam
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional sedation with midazolam and pethidine
Number of subjects: 37
Study: 23852679

Group type: EXPERIMENTAL
Intervention: CMV seronegative younger participants
Number of subjects: 107

Group type: COMPARATOR
Intervention: CMV seropositive younger participants
Number of subjects: 107

Group type: COMPARATOR
Intervention: CMV serostatus among older group
Number of subjects: 107
Study: 20490797

Group type: EXPERIMENTAL
Intervention: UFT (400 mg/m²/day for five consecutive days per week for 1 year)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 610
Study: 18710700

Group type: EXPERIMENTAL
Intervention: Children providing explanations for contamination
Number of subjects: 60

Group type: COMPARATOR
Intervention: Children making predictions for contamination
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Responses to varying desirability of contaminated substance (Study 2)
Number of subjects: 60
Study: 17077073

Group type: EXPERIMENTAL
Intervention: HMB (3 g/d for 7 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: HMB
Number of subjects: 34
Study: 14656658

Group type: EXPERIMENTAL
Intervention: Anterolateral (A‐L) THA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Posterolateral (P‐L) THA
Number of subjects: 29

Group type: COMPARATOR
Intervention: Able-bodied control group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Total THA patients (A‐L and P‐L combined)
Number of subjects: 29
Study: 11500188

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (lisinopril)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fibrates (fenofibrate)
Number of subjects: 39

Group type: COMPARATOR
Intervention: High fat meal
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low fat meal
Number of subjects: 39
Study: 9228228

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg or 20 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8131386

Group type: EXPERIMENTAL
Intervention: Lifetime BPD group (n = 13)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Active BPD group (n = 26)
Number of subjects: 39
Study: 28068656

Group type: EXPERIMENTAL
Intervention: FiO2 0.50 (oxygen-enriched air)
Number of subjects: 32

Group type: COMPARATOR
Intervention: FiO2 0.21 (ambient air)
Number of subjects: 32
Study: 26063762

Group type: EXPERIMENTAL
Intervention: Pharmacist prescribing (assessment of BP and cardiovascular risk, education on hypertension, prescribing of antihypertensive medications, laboratory monitoring, and monthly follow-up visits for 6 months)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Usual care from pharmacist and physician (wallet card for BP recording, written hypertension information)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Pharmacist prescribing
Number of subjects: 248
Study: 23607714

Group type: EXPERIMENTAL
Intervention: 1064 nm Q-switched Nd: YAG laser (1064 QSNY) for 10 sessions at 2-week intervals
Number of subjects: 26

Group type: COMPARATOR
Intervention: 1550 nm fractional photothermolysis (NFP) for five sessions at 4-week intervals
Number of subjects: 26
Study: 21929518

Group type: EXPERIMENTAL
Intervention: Vardenafil (10 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80